The ENCEL system: a somatic cell protein delivery system.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

The ENCEL system: a somatic cell protein delivery system.

In Vivo. 1994 Nov-Dec;8(5):771-80. Unique Identifier : AIDSLINE MED/95244808
Squinto SP; Madri JA; Kennedy S; Springhorn J; Alexion Pharmaceuticals, Inc, New Haven, CT 06511, USA.

Abstract: A wide variety of somatic cells are being explored for the introduction of foreign genes with a view toward gene therapy. A prime requirement for successful gene therapy is the sustained expression, effective dosing, and systemic delivery of the therapeutic gene product. Microvascular endothelial cells offer several advantages over other cell types as a somatic cell gene delivery vehicle in that they provide direct secretion of protein into the blood stream and they are amendable to highly stable retroviral-based protein expression. Importantly, they also offer a large surface volume to size ratio in that they can be induced with angiogenic factors to form organized capillary-like structures in vitro when grown in a three dimensional culture system using collagen gels. These genetically-modified capillary endothelial cells (the ENCEL system) maintained in collagen gels can be stably transplanted and removed. The unique biological properties of microvascular capillary endothelial cells allows the ENCEL system to provide large numbers of cells in a small volume which offers the highly desired opportunity for providing a sustained and effective dose of a therapeutic protein. Alexion is currently applying its Unigraft immunotherapeutic and engineering technologies to commercialize a non-human ENCEL system acceptable for implantation into any patient.

Keywords: Acquired Immunodeficiency Syndrome/THERAPY Animal Cytomegalovirus Infections/THERAPY *Drug Carriers Gene Therapy/*METHODS Hereditary Diseases/*THERAPY Human Immunologic Deficiency Syndromes/*THERAPY Neoplasms/*THERAPY Proteins/*ADMINISTRATION & DOSAGE Vaccines/ADMINISTRATION & DOSAGE JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL
950830
M9580951

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .